Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strides Fast-Tracks China Entry With JV As It Reports Strong Q1

Executive Summary

Indian firm Strides announces its entry into China through a joint venture with one of the country’s leading pharmaceutical firms, as first-quarter EBITDA soars 155%. 

You may also be interested in...



Strides’ Puducherry Plant Gets FDA Warning Letter

India’s Strides has received a warning letter from the US Food and Drug Administration over compliance issues at its Puducherry plant. However, the firm has told investors the regulatory action will not affect its forecast of 20% US sales growth for this financial year.

Bring Them On: China Releases Generics List To Encourage Competition

China's National Health Commission issues list of 34 generic drugs that have 'insufficient' competition, seeking public comments.

Strides' US Revenues Soar, Recovery Strategy ‘Executing To Plan’

Strides Pharma “very confident” about future after Indian generic company’s fourth-quarter US revenues rocketed 181% and EBITDA margins beat market expectations.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel